Eli Lilly and Company (NYSE:LLY) Stock Holdings Raised by Sycomore Asset Management

Sycomore Asset Management boosted its stake in Eli Lilly and Company (NYSE:LLY) by 206.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,013 shares of the company’s stock after acquiring an additional 26,282 shares during the quarter. Eli Lilly and Company comprises about 6.2% of Sycomore Asset Management’s holdings, making the stock its 3rd largest holding. Sycomore Asset Management’s holdings in Eli Lilly and Company were worth $35,161,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Heritage Oak Wealth Advisors LLC acquired a new position in Eli Lilly and Company in the 2nd quarter worth $371,000. New Wave Wealth Advisors LLC acquired a new position in shares of Eli Lilly and Company in the second quarter worth about $1,217,000. New Century Financial Group LLC lifted its stake in shares of Eli Lilly and Company by 10.0% in the second quarter. New Century Financial Group LLC now owns 2,185 shares of the company’s stock worth $1,978,000 after acquiring an additional 199 shares in the last quarter. Aldebaran Financial Inc. boosted its holdings in Eli Lilly and Company by 17.9% in the second quarter. Aldebaran Financial Inc. now owns 723 shares of the company’s stock valued at $655,000 after purchasing an additional 110 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in Eli Lilly and Company by 0.3% during the 2nd quarter. Cetera Investment Advisers now owns 224,922 shares of the company’s stock valued at $203,641,000 after purchasing an additional 603 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Barclays lifted their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price target for the company from $725.00 to $1,025.00 in a report on Monday, August 12th. Guggenheim raised their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Truist Financial restated a “buy” rating and issued a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Finally, JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Stock Up 0.9 %

Eli Lilly and Company stock opened at $885.56 on Tuesday. The firm has a market capitalization of $841.64 billion, a P/E ratio of 130.42, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a 50-day simple moving average of $896.50 and a 200-day simple moving average of $844.99. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the transaction, the insider now owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 364,810 shares of company stock valued at $339,366,198 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.